Summary of Key Points Core Viewpoint The company, Opcon Vision Technology Co., Ltd., is changing part of its fundraising purpose to acquire a 75% stake in Suqian Shangyue Qicheng Hospital Management Co., Ltd. This strategic move aims to enhance operational efficiency and align with the company's long-term development goals. Group 1: Fundraising and Financial Overview - The actual amount raised from the stock issuance was RMB 149,406.89 million after deducting issuance costs, with funds received in June 2022 [2][3]. - As of December 31, 2024, the company has utilized RMB 39,677.38 million of the raised funds, with a remaining balance of RMB 12,726.07 million after accounting for interest and investment income [3][4]. - The company plans to redirect RMB 23,373.00 million from the "Community Optical Service Terminal Construction Project" to fund the acquisition of Shangyue Qicheng [4][5]. Group 2: Acquisition Details - The total investment for acquiring a 75% stake in Shangyue Qicheng is RMB 33,390.00 million, with RMB 23,373.00 million sourced from the raised funds and RMB 10,017.00 million from the company's own funds [5][9]. - The acquisition aligns with the company's dual-driven development strategy of "full optical products + all-age optical services," enhancing its market presence in Yunnan Province [7][8]. - Shangyue Qicheng has established a comprehensive operational system and possesses strong brand recognition and profitability potential in the region [7][12]. Group 3: Financial Performance and Projections - Shangyue Qicheng's audited financial data shows total assets of RMB 11,073.59 million and net assets of RMB 6,151.34 million as of the latest report [14]. - The company has committed to achieving specific net profit targets from 2025 to 2029, with a minimum of RMB 3,900 million in 2025 [24]. - Future revenue growth is projected based on the expansion of service offerings and market penetration strategies, with a focus on medical services and optical products [21][22].

2025年4月10日，国家药品监督管理局（NMPA）公布，鹰瞳科技旗下的 Airdoc-AIFUNDUS 2.0眼底 病变眼底图像辅助诊断软件 通过三类医疗器械证审批，并在"第二十五届国际眼科学学术会议"与"第二十 五届国际视光学学术会议"（简称COOC 2025）上 首次亮相 ， 与配备万语大模型的鹰瞳Airdoc三大产 品线齐聚COOC 2025 ，共绘眼科和视光行业发展新蓝图。 # Airdoc-AIFUNDUS 2.0 眼底多病种AI诊断系统获NMPA认证 此次获批的 Airdoc-AIFUNDUS 2.0眼底病变眼底图像辅助诊断软件（简称Airdoc-AIFUNDUS 2.0） ， 在原有技术基础上取得新突破， 新增 视网膜静脉阻塞功能模块 。 这一获批标志着鹰瞳Airdoc在人工智能辅助诊断领域的技术实力和创新能力再度获得国家权威机构认可， 同时进一步强化了鹰瞳Airdoc在视网膜影像AI多病种诊断领域的领先地位。 | 2022年11月1日起,行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照,按照相关提示自行打印 | | --- | | 序 号 | 受理号 | 产品名称 | 申 ...